If you have concerns about receiving a cold-chain delivery, please contact our customer care team in advance
The Risks Common: Nausea, constipation, diarrhea
Weight regain risk during the transition Research consistently shows that approximately two-thirds of patients regain weight when they stop GLP-1 receptor agonist therapy
Most of this is water and glycogen, not fat
Most are gastrointestinal, dose-dependent, more common early in titration, and tend to ease with continued treatment
pharmacies Clinical oversight: Licensed providers available for unlimited free follow-up consultations Pricing transparency: No hidden fees Patient education: Comprehensive guidance on dosing, injection technique, storage, and side effect management Evidence-based protocol: Tirzepatide prescribing follows clinical trial-validated dose titration schedules Comprehensive approach: Treatment addresses metabolic root causes, not just symptomatic weight reduction Frequently Asked Questions What is GLP-1/GIP weight loss therapy, and how does it work
